LEGN.US 1548.HK

The latest: Genscript Biotech Corp. (1548.HK) announced Monday that its New York-listed subsidiary Legend Biotech Corp. (LEGN.US) will sell about 5.5 million new American Depositary Shares (ADSs) to an entity advised by T. Rowe Price for $64 per share.

Looking up: Legend expects to raise $350 million from the sale, which it will use for working capital and capital expenditures through the fourth quarter of 2025.

Take Note: The sale price represents a 4.5% discount to Legend Biotech’s Friday closing price of $66.99. Upon completion of the sale, Genscript’s shareholding in Legend will be diluted from 51.36% to 49.76%, meaning that its influence on the company will be slightly reduced.

Digging Deeper: Legend is Genscript’s cellular therapeutics business subsidiary. After years of spending, Legend’s new Cilta-cel product, being developed by a joint venture with Johnson & Johnson’s (JNJ.US) Janssen Biotech, accumulated sales of $206 million in the year since it was approved by the U.S. Food and Drug Administration (FDA) in last year’s first quarter.

Market Reaction: After opening up 2.1% on Monday, Genscript shares moved downward and closed 1.4% lower at HK$20.85 at the midday break. The stock now trades near the lower end of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Qudian abandons last mile delivery

Qudian: A slow-motion privatization?

The company said it is contemplating winding down its last-mile delivery service after stiff competition caused its revenue to plunge in the first quarter Key Takeaways: Qudian’s revenue fell by…
Yeahka secures bridgehead in U.S. payments market

Yeahka secures bridgehead in U.S. payments market

The Chinese fintech has cleared one of many regulatory hurdles to enter the U.S. digital payments business after gaining a state-level operating license Key Takeaways: After getting U.S. federal clearance,…
Sante makes infant nutritional products

Sainte Nutritional nurtures Hong Kong IPO

The Qingdao-based maker of food for special medical purposes is challenging international firms that still dominate the China market but could face tariff uncertainties Key Takeaways: Sainte Nutritional has filed…